Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.

[1]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[2]  K. Swedberg,et al.  Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial , 2013, European journal of heart failure.

[3]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[6]  M. Cho,et al.  Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. , 2013, International journal of cardiology.

[7]  M. Cho,et al.  The CKD-EPI is more accurate in clinical outcome prediction than MDRD equation in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. , 2013, International journal of cardiology.

[8]  C. Torp‐Pedersen,et al.  Patient adherence to evidence‐based pharmacotherapy in systolic heart failure and the transition of follow‐up from specialized heart failure outpatient clinics to primary care , 2013, European journal of heart failure.

[9]  Laura G. Qualls,et al.  Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. , 2013, American heart journal.

[10]  S. Kimmel,et al.  Blood Urea Nitrogen/Creatinine Ratio Identifies a High-Risk but Potentially Reversible Form of Renal Dysfunction in Patients With Decompensated Heart Failure , 2013, Circulation. Heart failure.

[11]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[12]  L. Lund,et al.  Association of Spironolactone Use With All-Cause Mortality in Heart Failure: A Propensity Scored Cohort Study , 2013, Circulation. Heart failure.

[13]  Ali Ahmed,et al.  Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. , 2013, JACC. Heart failure.

[14]  Deepak L. Bhatt,et al.  Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. , 2013, Journal of the American College of Cardiology.

[15]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[16]  Laura G. Qualls,et al.  Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. , 2012, JAMA.

[17]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[18]  P. Pibarot,et al.  The impact of complete revascularization on long-term survival is strongly dependent on age. , 2012, The Annals of thoracic surgery.

[19]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[20]  M. Walsh,et al.  Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. , 2012, Journal of cardiac failure.

[21]  L. Sandvik,et al.  Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. , 2012, Journal of the American College of Cardiology.

[22]  S. Kimmel,et al.  Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials , 2011, European journal of heart failure.

[23]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[24]  C. Brensinger,et al.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. , 2011, Journal of the American College of Cardiology.

[25]  Eun-Seok Jeon,et al.  Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry , 2011, Korean circulation journal.

[26]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[27]  M. Horie,et al.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. , 2010, American heart journal.

[28]  Y. Jang,et al.  Relation between red cell distribution width with echocardiographic parameters in patients with acute heart failure. , 2009, Journal of cardiac failure.

[29]  Yen-Hung Lin,et al.  Elevated blood urea nitrogen-to-creatinine ratio increased the risk of hospitalization and all-cause death in patients with chronic heart failure , 2009, Clinical Research in Cardiology.

[30]  N. Abutaleb.  Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[32]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[33]  Harlan M Krumholz,et al.  Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. , 2003, American heart journal.

[34]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[35]  M. Lauer,et al.  Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. , 2001, JAMA.

[36]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[37]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[38]  Ralph B. D'Agostino.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 1998, Statistics in medicine.

[39]  J. Ferreira,et al.  Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. , 2014, European journal of internal medicine.

[40]  J. McMurray,et al.  SAFETY AND EFFICACY OF EPLERENONE IN PATIENTS AT HIGH RISK FOR HYPERKALEMIA AND/OR WORSENING RENAL FUNCTION. ANALYSES OF THE EMPHASIS-HF STUDY SUBGROUPS (EPLERENONE IN MILD PATIENTS HOSPITALIZATION AND SURVIVAL STUDY IN HEART FAILURE) , 2014 .

[41]  Seung‐Jung Park,et al.  Short- and long-term outcomes depending on electrical dyssynchrony markers in patients presenting with acute heart failure: clinical implication of the first-degree atrioventricular block and QRS prolongation from the Korean Heart Failure registry. , 2013, American heart journal.

[42]  Y. Jang,et al.  Prognostic value of change in red cell distribution width 1 month after discharge in acute decompensated heart failure patients. , 2012, Circulation journal : official journal of the Japanese Circulation Society.